全文获取类型
收费全文 | 2936598篇 |
免费 | 222341篇 |
国内免费 | 33018篇 |
专业分类
耳鼻咽喉 | 37008篇 |
儿科学 | 89767篇 |
妇产科学 | 75514篇 |
基础医学 | 401511篇 |
口腔科学 | 75473篇 |
临床医学 | 285463篇 |
内科学 | 561587篇 |
皮肤病学 | 66238篇 |
神经病学 | 230046篇 |
特种医学 | 113016篇 |
外国民族医学 | 960篇 |
外科学 | 416889篇 |
综合类 | 119553篇 |
现状与发展 | 91篇 |
一般理论 | 994篇 |
预防医学 | 222025篇 |
眼科学 | 66768篇 |
药学 | 226957篇 |
439篇 | |
中国医学 | 29483篇 |
肿瘤学 | 172175篇 |
出版年
2022年 | 21956篇 |
2021年 | 37605篇 |
2020年 | 26443篇 |
2019年 | 31864篇 |
2018年 | 40865篇 |
2017年 | 33866篇 |
2016年 | 36447篇 |
2015年 | 45686篇 |
2014年 | 60703篇 |
2013年 | 78689篇 |
2012年 | 107341篇 |
2011年 | 115137篇 |
2010年 | 71777篇 |
2009年 | 66001篇 |
2008年 | 99446篇 |
2007年 | 103948篇 |
2006年 | 104733篇 |
2005年 | 100116篇 |
2004年 | 90661篇 |
2003年 | 87653篇 |
2002年 | 82770篇 |
2001年 | 135824篇 |
2000年 | 138659篇 |
1999年 | 118003篇 |
1998年 | 36280篇 |
1997年 | 32763篇 |
1996年 | 32024篇 |
1995年 | 30976篇 |
1994年 | 28078篇 |
1993年 | 25331篇 |
1992年 | 87250篇 |
1991年 | 83424篇 |
1990年 | 80357篇 |
1989年 | 77421篇 |
1988年 | 70577篇 |
1987年 | 68959篇 |
1986年 | 64337篇 |
1985年 | 61073篇 |
1984年 | 45251篇 |
1983年 | 38166篇 |
1982年 | 22569篇 |
1979年 | 39062篇 |
1978年 | 27491篇 |
1977年 | 23291篇 |
1976年 | 21521篇 |
1975年 | 22835篇 |
1974年 | 26818篇 |
1973年 | 25393篇 |
1972年 | 23780篇 |
1971年 | 21970篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
21.
22.
23.
24.
Immunoglobulin light chain amyloidosis (AL) commonly presents with nephrotic range proteinuria, heart failure with preserved ejection fraction, nondiabetic peripheral neuropathy, unexplained hepatomegaly or diarrhea, and should be considered in patients presenting with these symptoms. More importantly, patients being monitored for smoldering multiple myeloma and a monoclonal gammopathy of undetermined significance (MGUS) are at risk for developing AL amyloidosis. MGUS and myeloma patients that have atypical features, including unexplained weight loss; lower extremity edema, early satiety, and dyspnea on exertion should be considered at risk for light chain amyloidosis. Overlooking the diagnosis of light chain amyloidosis leading to therapy delay is common, and it represents an error of diagnostic consideration. Herein we provide a review of established and investigational treatments for patients with AL amyloidosis and provide algorithms for workup and management of these patients.Subject terms: Myeloma, Chemotherapy 相似文献
25.
Melanie A. Krook Julie W. Reeser Gabrielle Ernst Hannah Barker Max Wilberding Gary Li Hui-Zi Chen Sameek Roychowdhury 《British journal of cancer》2021,124(5):880
Fibroblast growth factor receptors (FGFRs) are aberrantly activated through single-nucleotide variants, gene fusions and copy number amplifications in 5–10% of all human cancers, although this frequency increases to 10–30% in urothelial carcinoma and intrahepatic cholangiocarcinoma. We begin this review by highlighting the diversity of FGFR genomic alterations identified in human cancers and the current challenges associated with the development of clinical-grade molecular diagnostic tests to accurately detect these alterations in the tissue and blood of patients. The past decade has seen significant advancements in the development of FGFR-targeted therapies, which include selective, non-selective and covalent small-molecule inhibitors, as well as monoclonal antibodies against the receptors. We describe the expanding landscape of anti-FGFR therapies that are being assessed in early phase and randomised controlled clinical trials, such as erdafitinib and pemigatinib, which are approved by the Food and Drug Administration for the treatment of FGFR3-mutated urothelial carcinoma and FGFR2-fusion cholangiocarcinoma, respectively. However, despite initial sensitivity to FGFR inhibition, acquired drug resistance leading to cancer progression develops in most patients. This phenomenon underscores the need to clearly delineate tumour-intrinsic and tumour-extrinsic mechanisms of resistance to facilitate the development of second-generation FGFR inhibitors and novel treatment strategies beyond progression on targeted therapy.Subject terms: Cancer, Cancer 相似文献
26.
27.
28.
29.
Depeng Meng Yichen Meng Bingyang Li Guigang Zeng Bin Zhang Chunlin Hou Haodong Lin Yueping Ouyang 《Journal of orthopaedic science》2021,26(3):409-414
BackgroundComminuted patellar fractures are not rare, and the ideal treatment method remains controversial. The present study was conducted to evaluate effects and compare complications of two different methods used to treat comminuted patellar fractures.MethodsFrom March 2010 to August 2016, 102 cases of 34-C2 or 34-C3 comminuted patellar fractures were treated at our hospital, wherein patients received two different treatments: titanium cable tension band with cerclage method (group A) and intrafragmentary screws with X-shaped plating technique (group B). At follow-ups, articular step-off, range of motion (ROM), Lysholm scores, time of union, and complications were recorded and analyzed. Radiographic and clinical data as well as rate of complications were statistically analyzed.ResultsIn total, 87 patients were included in the final analysis (n = 47 in group A and n = 40 in group B). No significant differences were noted in terms of cost of implant, age, gender, rate of 34-C3 fractures, rate of layered inferior pole fractures, postoperative articular step-off and union time. At 2-year follow-up, average Lysholm scores, ROM and rate of complications were (89.0 ± 4.5), (122°±12°) and (27.7%) in group A and (90.2 ± 3.9), (124°±11°) and (17.5%) in group B, respectively, with no significant differences (p > 0.05). The mean time of surgery in group B was shorter than that in group A with significant difference (p < 0.05).ConclusionsTreatment using the intrafragmentary screws and plate method for amenable comminuted patellar fractures achieved similar complication rate and favorable functional outcomes at the 2-year follow-up, which was comparable to the titanium cable tension band with cerclage method. Thus, the intrafragmentary screws and plate method is effective, safe and convenient for 34-C2/C3 comminuted patellar fractures, especially appropriate for patients with layered fragments. 相似文献
30.
Yuxiang Ma Wenfeng Fang Hongyun Zhao Sai Praneeth Bathena Amol Tendolkar Jennifer Sheng Li Zhang 《The oncologist》2021,26(4):e549-e566
Lessons Learned
- The overall safety profiles of ipilimumab 3 mg/kg and 10 mg/kg administered every 3 weeks, were consistent between Chinese patients with solid tumors in the current study and patients from previous U.S. ipilimumab monotherapy studies. No new safety signals were identified.
- The mean systemic exposures to ipilimumab (assessed by first dose area under the curve during the dosing interval and maximum serum concentration) were numerically lower in the Chinese patient population than in U.S. patients for both 3 mg/kg and 10 mg/kg doses; however, the range of serum concentrations in the Chinese and U.S. populations overlapped (3 mg/kg and 10 mg/kg), suggesting that ipilimumab pharmacokinetics was ethnically insensitive in this study.